MARLBOROUGH, Mass., May 10, 2017 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced the schedule of key data
"This year's EuroPCR congress will provide us the opportunity to share the performance of our LOTUS Valve platform in the REPRISE III trial,which is the first large, global, randomized head-to-head trial of two contemporary TAVI valves, as well as findings from the RESPOND and RESPOND Extension studies," said Ian Meredith, M.D., executive vice president and global chief medical officer, Boston Scientific. "These data, along with findings from the European registry for the WATCHMAN device, further demonstrate the value our minimally-invasive structural heart therapies bring to physicians in their pursuit of delivering the highest quality care to their patients."
SCHEDULE OF PRESENTATIONS OF INTEREST (listed chronologically)
Tuesday, May 16
Wednesday, May 17
Thursday, May 18
All events are listed in Central European Summer Time (CEST) and take place at the Palais des Congrès. For additional details about Boston Scientific data presentations and sponsored symposia, go to www.bostonscientific.com/EuroPCR2017 or visit the Boston Scientific booth located on Level 1, Hall Passy F21.
The company will also host an investor event and webcast on Tuesday, May 16, from 16:00 to 17:00 (CEST)/ 10:00 to 11:00 AM (EDT) to discuss its interventional cardiology and structural heart portfolios. The live webcast and replay will be accessible at www.bostonscientific.com/investors with the latter becoming available approximately one hour following the completion of the event.
*The LOTUS™ valve system is currently not available for use or sale.**In the U.S., the Agent™ Paclitaxel-Coated balloon catheter is investigational and not available for sale.
About Boston ScientificBoston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.
U.S. Media: Trish Backes(612) 296-8067Trish.Backes@bsci.com
European Media: Chiara Ennas+44 (0) 7766 086882Chiara.Ennas@bsci.com
Investor Relations: Susie Lisa, CFA(508) 683-5565 (office)firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/boston-scientific-announces-schedule-of-presentations-at-europcr-2017-300454820.html
SOURCE Boston Scientific Corporation
Subscribe to our Free Newsletters!
HELLP syndrome is a rare but serious complication that affects pregnant women. If detected on time, ...
Discectomy is a surgical procedure in which a herniated (bulged) disc that compresses the nerves of ...
Parotidectomy is a surgery to remove a part of or the entire parotid salivary gland, on the side of ...View All